The impact of biologic therapy in chronic plaque psoriasis from a societal perspective

An analysis based on Italian actual clinical practice

B. Polistena, P. Calzavara-Pinton, G. Altomare, E. Berardesca, G. Girolomoni, P. Martini, A. Peserico, A. Puglisi Guerra, F. Spandonaro, A. Vena Gino, S. Chimenti, F. Ayala

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective Psoriasis is one of the most common forms of chronic dermatitis, affecting 2-3% of the worldwide population. It has a serious effect on the way patients perceive themselves and others, thereby prejudicing their quality of life and giving rise to a significant deterioration in their psycho-physical well-being; it also poses greater difficulties for them in leading a normal social life, including their ability to conduct a normal working life. All the above-mentioned issues imply a cost for the society. This study proposes to evaluate the impact on societal costs for the treatment of chronic plaque psoriasis with biologics (etanercept, infliximab and adalimumab) in the Italian clinical practice. Method A prospective observational study has been conducted in 12 specialized centres of the Psocare network, located throughout Italy. Direct and indirect costs (as well as the health-related quality of life of patients with plaque psoriasis undergoing biologic treatments) have been estimated, while the societal impact has been determined using a cost-utility approach. Results Non-medical and indirect costs account for as much as 44.97% of the total cost prior to treatment and to 6.59% after treatment, with an overall 71.38% decrease. Adopting a societal perspective in the actual clinical practice of the Italian participating centres, the ICER of biologic therapies for treating plaque psoriasis amounted to €18634.40 per QALY gained - a value far from the €28656.30 obtained by adopting a third-party payer perspective. Conclusion Our study confirms that chronic psoriasis subjects patients to a considerable burden, together with their families and caregivers, stressing how important it is to take the societal perspective into consideration during the appraisal process. Besides, using data derived from Italian actual practice, treatment with biologics shows a noteworthy benefit in social terms.

Original languageEnglish
Pages (from-to)2411-2416
Number of pages6
JournalJournal of the European Academy of Dermatology and Venereology
Volume29
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Biological Therapy
Psoriasis
Costs and Cost Analysis
Biological Products
Quality of Life
Health Insurance Reimbursement
Quality-Adjusted Life Years
Dermatitis
Therapeutics
Health Care Costs
Italy
Caregivers
Observational Studies
Prospective Studies
Population

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

The impact of biologic therapy in chronic plaque psoriasis from a societal perspective : An analysis based on Italian actual clinical practice. / Polistena, B.; Calzavara-Pinton, P.; Altomare, G.; Berardesca, E.; Girolomoni, G.; Martini, P.; Peserico, A.; Puglisi Guerra, A.; Spandonaro, F.; Vena Gino, A.; Chimenti, S.; Ayala, F.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 29, No. 12, 01.12.2015, p. 2411-2416.

Research output: Contribution to journalArticle

Polistena, B, Calzavara-Pinton, P, Altomare, G, Berardesca, E, Girolomoni, G, Martini, P, Peserico, A, Puglisi Guerra, A, Spandonaro, F, Vena Gino, A, Chimenti, S & Ayala, F 2015, 'The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: An analysis based on Italian actual clinical practice', Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 12, pp. 2411-2416. https://doi.org/10.1111/jdv.13307
Polistena, B. ; Calzavara-Pinton, P. ; Altomare, G. ; Berardesca, E. ; Girolomoni, G. ; Martini, P. ; Peserico, A. ; Puglisi Guerra, A. ; Spandonaro, F. ; Vena Gino, A. ; Chimenti, S. ; Ayala, F. / The impact of biologic therapy in chronic plaque psoriasis from a societal perspective : An analysis based on Italian actual clinical practice. In: Journal of the European Academy of Dermatology and Venereology. 2015 ; Vol. 29, No. 12. pp. 2411-2416.
@article{d9bce7aeb0d44de1aa15aa9e24c35d10,
title = "The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: An analysis based on Italian actual clinical practice",
abstract = "Objective Psoriasis is one of the most common forms of chronic dermatitis, affecting 2-3{\%} of the worldwide population. It has a serious effect on the way patients perceive themselves and others, thereby prejudicing their quality of life and giving rise to a significant deterioration in their psycho-physical well-being; it also poses greater difficulties for them in leading a normal social life, including their ability to conduct a normal working life. All the above-mentioned issues imply a cost for the society. This study proposes to evaluate the impact on societal costs for the treatment of chronic plaque psoriasis with biologics (etanercept, infliximab and adalimumab) in the Italian clinical practice. Method A prospective observational study has been conducted in 12 specialized centres of the Psocare network, located throughout Italy. Direct and indirect costs (as well as the health-related quality of life of patients with plaque psoriasis undergoing biologic treatments) have been estimated, while the societal impact has been determined using a cost-utility approach. Results Non-medical and indirect costs account for as much as 44.97{\%} of the total cost prior to treatment and to 6.59{\%} after treatment, with an overall 71.38{\%} decrease. Adopting a societal perspective in the actual clinical practice of the Italian participating centres, the ICER of biologic therapies for treating plaque psoriasis amounted to €18634.40 per QALY gained - a value far from the €28656.30 obtained by adopting a third-party payer perspective. Conclusion Our study confirms that chronic psoriasis subjects patients to a considerable burden, together with their families and caregivers, stressing how important it is to take the societal perspective into consideration during the appraisal process. Besides, using data derived from Italian actual practice, treatment with biologics shows a noteworthy benefit in social terms.",
author = "B. Polistena and P. Calzavara-Pinton and G. Altomare and E. Berardesca and G. Girolomoni and P. Martini and A. Peserico and {Puglisi Guerra}, A. and F. Spandonaro and {Vena Gino}, A. and S. Chimenti and F. Ayala",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/jdv.13307",
language = "English",
volume = "29",
pages = "2411--2416",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "12",

}

TY - JOUR

T1 - The impact of biologic therapy in chronic plaque psoriasis from a societal perspective

T2 - An analysis based on Italian actual clinical practice

AU - Polistena, B.

AU - Calzavara-Pinton, P.

AU - Altomare, G.

AU - Berardesca, E.

AU - Girolomoni, G.

AU - Martini, P.

AU - Peserico, A.

AU - Puglisi Guerra, A.

AU - Spandonaro, F.

AU - Vena Gino, A.

AU - Chimenti, S.

AU - Ayala, F.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objective Psoriasis is one of the most common forms of chronic dermatitis, affecting 2-3% of the worldwide population. It has a serious effect on the way patients perceive themselves and others, thereby prejudicing their quality of life and giving rise to a significant deterioration in their psycho-physical well-being; it also poses greater difficulties for them in leading a normal social life, including their ability to conduct a normal working life. All the above-mentioned issues imply a cost for the society. This study proposes to evaluate the impact on societal costs for the treatment of chronic plaque psoriasis with biologics (etanercept, infliximab and adalimumab) in the Italian clinical practice. Method A prospective observational study has been conducted in 12 specialized centres of the Psocare network, located throughout Italy. Direct and indirect costs (as well as the health-related quality of life of patients with plaque psoriasis undergoing biologic treatments) have been estimated, while the societal impact has been determined using a cost-utility approach. Results Non-medical and indirect costs account for as much as 44.97% of the total cost prior to treatment and to 6.59% after treatment, with an overall 71.38% decrease. Adopting a societal perspective in the actual clinical practice of the Italian participating centres, the ICER of biologic therapies for treating plaque psoriasis amounted to €18634.40 per QALY gained - a value far from the €28656.30 obtained by adopting a third-party payer perspective. Conclusion Our study confirms that chronic psoriasis subjects patients to a considerable burden, together with their families and caregivers, stressing how important it is to take the societal perspective into consideration during the appraisal process. Besides, using data derived from Italian actual practice, treatment with biologics shows a noteworthy benefit in social terms.

AB - Objective Psoriasis is one of the most common forms of chronic dermatitis, affecting 2-3% of the worldwide population. It has a serious effect on the way patients perceive themselves and others, thereby prejudicing their quality of life and giving rise to a significant deterioration in their psycho-physical well-being; it also poses greater difficulties for them in leading a normal social life, including their ability to conduct a normal working life. All the above-mentioned issues imply a cost for the society. This study proposes to evaluate the impact on societal costs for the treatment of chronic plaque psoriasis with biologics (etanercept, infliximab and adalimumab) in the Italian clinical practice. Method A prospective observational study has been conducted in 12 specialized centres of the Psocare network, located throughout Italy. Direct and indirect costs (as well as the health-related quality of life of patients with plaque psoriasis undergoing biologic treatments) have been estimated, while the societal impact has been determined using a cost-utility approach. Results Non-medical and indirect costs account for as much as 44.97% of the total cost prior to treatment and to 6.59% after treatment, with an overall 71.38% decrease. Adopting a societal perspective in the actual clinical practice of the Italian participating centres, the ICER of biologic therapies for treating plaque psoriasis amounted to €18634.40 per QALY gained - a value far from the €28656.30 obtained by adopting a third-party payer perspective. Conclusion Our study confirms that chronic psoriasis subjects patients to a considerable burden, together with their families and caregivers, stressing how important it is to take the societal perspective into consideration during the appraisal process. Besides, using data derived from Italian actual practice, treatment with biologics shows a noteworthy benefit in social terms.

UR - http://www.scopus.com/inward/record.url?scp=84959331194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959331194&partnerID=8YFLogxK

U2 - 10.1111/jdv.13307

DO - 10.1111/jdv.13307

M3 - Article

VL - 29

SP - 2411

EP - 2416

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 12

ER -